NRAS and neoplasm: Among MM drivers, somatic mutations of NRAS and the TERT promoter are reported, as well as mutually exclusive loss of function mutation of the tumor suppressors NF1 and SPRED1, the latter co-occurring with activating KIT mutations [10–12].